Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 3:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Egg Dose Clear all
Completed Phase 2 Interventional Results available

Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy

NCT01846208
View directory record Official record
Conditions
Food Allergy
Interventions
Egg Oral Immunotherapy, Baked Egg
Drug
Lead sponsor
Hugh A Sampson, MD
Other
Eligibility
3 Years to 16 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Development of Childhood Anti-Influenza Immunity

NCT03673345
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Quadrivalent Inactivated Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 15 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults

NCT02624219
View directory record Official record
Conditions
Avian Influenza, Influenza
Interventions
AS03, MF59 adjuvant, Monovalent Influenza A/H5N8 vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
4
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN

NCT00672854
View directory record Official record
Conditions
Parenteral Nutrition
Interventions
ClinOleic 20% Intravenous Emulsion, Intralipid, 20% Intravenous Emulsion
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 23, 2026, 3:59 AM EDT
Terminated Phase 2 Interventional Results available

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

NCT04056299
View directory record Official record
Conditions
Hen Egg Allergy
Interventions
AR201 powder, Placebo powder
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 26 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Little Rock, Arkansas • Rolling Hills Estates, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

NCT03318315
View directory record Official record
Conditions
Avian Influenza, Influenza, Influenza Immunisation
Interventions
AS03, Inactivated influenza H7N9 vaccine, Influenza Virus Quadrivalent Inactivated Vaccine, Phosphate Buffered Saline (PBS) diluent
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Not applicable Interventional

IVF Clinical Trial of Two Different Treatment Protocols.

NCT00799929
View directory record Official record
Conditions
Infertility
Interventions
in vitro fertilization (IVF/ICSI)
Other
Lead sponsor
New Hope Fertility Center
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults

NCT04576702
View directory record Official record
Conditions
Influenza, Human
Interventions
Investigational aIIV4c, IIV4c, aIIV4, RIV4
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years and older
Enrollment
471 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
21
States / cities
Mobile, Alabama • Tempe, Arizona • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease

NCT01434693
View directory record Official record
Conditions
Crohn's Disease
Interventions
Trichuris suis ova, Placebo
Biological · Other
Lead sponsor
Coronado Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
Anaheim, California • Jacksonville, Florida • Winter Park, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 19, 2013 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults

NCT00264576
View directory record Official record
Conditions
Influenza Disease; Flu
Interventions
Influenza Virus Vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 49 Years
Enrollment
613 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
4
States / cities
Bardstown, Kentucky • Pittsburgh, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 23, 2026, 3:59 AM EDT
Recruiting Phase 2 Interventional

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

NCT05947071
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza
Interventions
Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

Oral Immunotherapy for Childhood Egg Allergy

NCT00461097
View directory record Official record
Conditions
Hypersensitivity, Immediate Hypersensitivity, Food Hypersensitivity
Interventions
Egg oral immunotherapy, Control Group
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 18 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 23, 2026, 3:59 AM EDT
Completed No phase listed Observational

Once Daily vs Twice Daily Administration of Gonadotropins in Assisted Reproductive Technologies (ART)

NCT00740025
View directory record Official record
Conditions
Pregnancy
Interventions
Not listed
Lead sponsor
Virginia Center for Reproductive Medicine
Other
Eligibility
21 Years to 39 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Reston, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

NCT04856865
View directory record Official record
Conditions
Food Allergy
Interventions
Low dose ADP101, High dose ADP101, Pooled Placebo
Biological
Lead sponsor
Alladapt Immunotherapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults

NCT01574638
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifapentine (RPT)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
San Diego, California • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 23, 2026, 3:59 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ketone Conferred Resiliency Against Sleep Restriction With Nutritional Intervention.

NCT06075914
View directory record Official record
Conditions
Sleep Deprivation, Nutritional Intervention
Interventions
Ketogenic Intervention, Mediterranean Intervention, Placebo, Ketone Ester
Other · Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years

NCT05514002
View directory record Official record
Conditions
Influenza, Human
Interventions
Fluzone Quadrivalent, Flublok Quadrivalent
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 64 Years
Enrollment
3,988 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Tucson, Arizona • Tallahassee, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 23, 2026, 3:59 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder

NCT02140112
View directory record Official record
Conditions
Autism
Interventions
Trichuris suis ova, Placebo
Biological · Other
Lead sponsor
Coronado Biosciences, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Naperville, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 23, 2026, 3:59 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Effect of Influenza Vaccination on Donor Egg Recipient Outcomes

NCT02946177
View directory record Official record
Conditions
Infertility, Recurrent Miscarriage
Interventions
Influenza Vaccine, Sterile Saline
Biological · Other
Lead sponsor
Center for Human Reproduction
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Sep 23, 2026, 3:59 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS

NCT02087826
View directory record Official record
Conditions
Genetics, Metabolism, Type 2 Diabetes
Interventions
Mixed Meal Tolerance Test, Metformin
Other · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
1,017 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 23, 2026, 3:59 AM EDT
Terminated Phase 2 Interventional Results available

Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis

NCT01953354
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Trichuris suis ova (TSO), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Palo Alto, California • New Haven, Connecticut • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 23, 2026, 3:59 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.

NCT07779408
View directory record Official record
Conditions
Healthy Volunteers, Influenza
Interventions
Flu H5 egg pandemic low dose vaccine, with adjuvant, Flu H5 Egg Pandemic medium dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, without adjuvant
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
16
States / cities
Tempe, Arizona • Rolling Hills Estates, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age

NCT01857206
View directory record Official record
Conditions
Influenza, Fever
Interventions
Mammalian cell based flu vaccine, Egg based flu vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
4 Years to 17 Years
Enrollment
2,055 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
18
States / cities
Mobile, Alabama • Ponte Vedra, Florida • Augusta, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696
View directory record Official record
Conditions
Peanut Allergy, Multi-food Allergy
Interventions
Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 23, 2026, 3:59 AM EDT